Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-06-30
2010-10-05
Angell, J. E (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
07807815
ABSTRACT:
The present invention provides siRNA molecules and methods of using such siRNA molecules to modulate an immune response and to silence expression of a target gene.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4438052 (1984-03-01), Weder et al.
patent: 4515736 (1985-05-01), Deamer
patent: 4598051 (1986-07-01), Papahadjopoulos et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5171678 (1992-12-01), Behr et al.
patent: 5208036 (1993-05-01), Eppstein et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5279833 (1994-01-01), Rose
patent: 5283185 (1994-02-01), Epand et al.
patent: 5320906 (1994-06-01), Eley et al.
patent: 5545412 (1996-08-01), Eppstein et al.
patent: 5578475 (1996-11-01), Jessee et al.
patent: 5641662 (1997-06-01), Debs et al.
patent: 5656743 (1997-08-01), Busch et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5705385 (1998-01-01), Bally et al.
patent: 5820873 (1998-10-01), Choi et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981501 (1999-11-01), Wheeler et al.
patent: 6534484 (2003-03-01), Wheeler et al.
patent: 6586410 (2003-07-01), Wheeler et al.
patent: 6649780 (2003-11-01), Eibl et al.
patent: 6680068 (2004-01-01), Campbell et al.
patent: 6815432 (2004-11-01), Wheeler et al.
patent: 6858224 (2005-02-01), Wheeler et al.
patent: 7341738 (2008-03-01), Semple et al.
patent: 2003/0073640 (2003-04-01), Beigelman et al.
patent: 2003/0077829 (2003-04-01), MacLachlan
patent: 2003/0125263 (2003-07-01), Gold et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0063654 (2004-04-01), Davis et al.
patent: 2004/0142892 (2004-07-01), Finn et al.
patent: 2004/0192626 (2004-09-01), McSwiggen et al.
patent: 2004/0198640 (2004-10-01), Leake et al.
patent: 2004/0248299 (2004-12-01), Jayasena et al.
patent: 2004/0253723 (2004-12-01), Tachas et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0020525 (2005-01-01), McSwiggen et al.
patent: 2005/0064595 (2005-03-01), MacLachlan et al.
patent: 2005/0119214 (2005-06-01), Manoharan et al.
patent: 2005/0282188 (2005-12-01), Haeberli et al.
patent: 2006/0008910 (2006-01-01), MacLachlan et al.
patent: 2006/0083780 (2006-04-01), Heyes et al.
patent: 2006/0105976 (2006-05-01), Soutschek et al.
patent: 2006/0240554 (2006-10-01), Chen et al.
patent: 2007/0042983 (2007-02-01), Haeberli et al.
patent: 2007/0135370 (2007-06-01), MacLachlan et al.
patent: 2359180 (2000-08-01), None
patent: WO 91/16024 (1991-10-01), None
patent: WO 93/05162 (1993-03-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO 93/12756 (1993-07-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/02698 (1995-01-01), None
patent: WO 95/18863 (1995-07-01), None
patent: WO 95/35301 (1995-12-01), None
patent: WO 96/02655 (1996-02-01), None
patent: WO 96/10390 (1996-04-01), None
patent: WO 96/41873 (1996-12-01), None
patent: WO 98/51278 (1998-11-01), None
patent: WO 01/05374 (2001-01-01), None
patent: WO 02/34236 (2002-05-01), None
patent: WO 02/072068 (2002-09-01), None
patent: WO 02/087541 (2002-11-01), None
patent: WO 03/029453 (2003-04-01), None
patent: WO 03/086280 (2003-10-01), None
patent: WO 03/097805 (2003-11-01), None
patent: WO 2004/029212 (2004-04-01), None
patent: WO 2004/046324 (2004-06-01), None
patent: WO 2004/065546 (2004-08-01), None
patent: WO 2004/110499 (2004-12-01), None
patent: WO 2005/007196 (2005-01-01), None
patent: WO 2005/019453 (2005-03-01), None
patent: WO 2005/021044 (2005-03-01), None
patent: WO 2005/026372 (2005-03-01), None
patent: WO 2005/044981 (2005-05-01), None
patent: WO 2005/078094 (2005-08-01), None
patent: WO 2005/120152 (2005-12-01), None
patent: WO 2005/121348 (2005-12-01), None
patent: WO 2006/074546 (2006-07-01), None
patent: WO 2007/048046 (2007-04-01), None
Hamada, et al. (2002) Antisenseand Nucleic Acid Drug Development, v.12:301-9).
Nguyen, et al. (2008) RNAI Therapeutics: An Update on Delivery. Current Opinion in Molecular Therapeutics, v.10(2):158-67.
Aoki, H. et al. “Inhibition of motility and invasiveness of renal cell carcinoma induced by short interfering RNA transfection of β1, 4GaINAc transferase.”FEBS Letters(2004), 567:203-208.
Dalby, B. et al. “Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications”Methods(2004), 33(2):95-103.
Flynn, M.A. et al. “Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo.”Journal of Inflammation(Oct. 2004), 1(4):1-12.
GenBank accession No. BD134629 from JP 2002051788 patent application (Komori Toshifumii), Feb. 19, 2002.
Heil, F. et al. “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8.”Science(Mar. 2004), 303:1526-1529.
Judge, A.D. et al. “Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.”Nature Biotechnology(Apr. 2005), 23(4):457-462.
Martinez, A. et al. “Small Interfering RNA Molecules as Potential Anti-Human Hepatitis C Virus Agents: Identification and Characterization of Two siRNA Molecules Highly Conserved in the Major Genotypes of the Virus.”Preclinica. (Nov./Dec. 2003), 1(5):274-283.
Sioud, M. “Induction of Inflammatory Cytokines and Interferon Responses by Double-stranded and Single-stranded siRNAs is Sequence-dependent and Requires Endosomal Localization.”Journal of Molecular Biology(2005), 348:1079-1090.
Ballas, N. et al., “Liposomes bearing a quarternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts,”Biochim. Biophys. Acta, 1998. pp. 8-18, vol. 939.
Barinaga, M., “Step Taken Toward Improved Vectors for Gene Transfer,”Science, 1994, p. 1326, vol. 266.
Behr, J-P., “Synthetic Gene-Transfer Vectors,”Acc. Chem. Res. 1993, pp. 274-278, vol. 26.
Brigham, K. et al., “Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle,”Am. J. Med. Sci., 1989, pp. 278-281, vol. 298.
Cortesi, R., et al., “Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA,”International Journal of Pharmaceutics, 1996, pp. 69-78, vol. 139.
Crystal, R., “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,”Science, 1995, pp. 404-410, vol. 270.
Culver K.,, “The First Human Gene Therapy Experiment,”Gene Therapy: A Handbook for Physicians, 1994, pp. 33-40.
Duzgunes, N., “Membrane Fusion,”Subcellular Biochemistry, 1985, pp. 195-286, vol. 11.
Dwarki, V.J., et al., “Cationic Liposime-Mediated RNA Transfection,”Methods in Enzymology, 1993, pp. 644-654, vol. 217.
Enoch, H. et al., “Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles,”Proc. Natl. Acad. Sci. USA, 1979, pp. 145-149, vol. 76, No. 1.
Felgner, P. et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA, 1987, pp. 7413-7417, vol. 84.
Felgner, J.H., et al., “Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations,”The Journal of Biological Chemistry, Jan. 1994, pp. 2550-2561, vol. 269, No. 4.
Felgner, J., et al., “Cationic Lipid-Mediated Transfection in Mammalian Cells: “Lipofection”,”J. Tiss. Cult. Meth., 1993, pp. 63-68, vol. 15.
Felgner, P.L., et al., “Cationic Liposome Mediated Transfection,”Proc. West. Pharmacol. Soc., 1989, pp. 115-121, vol. 32.
Gao, X. et al., “A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells,”Biochem. Biophys. Res. Comm., 1991, pp. 280-285, vol. 179.
Gershon, H. et al., “Mode of Formation and Structural Feature of DNA-Cationic Liposome Complexes Used for Transfection,”Bioc
Heyes James
Judge Adam
MacLachlan Ian
Palmer Lorne
Angell J. E
Protiva Biotherapeutics Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Compositions comprising immunostimulatory siRNA molecules... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising immunostimulatory siRNA molecules..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising immunostimulatory siRNA molecules... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239823